Literature DB >> 34348160

Exploring the longitudinal glioma microenvironment landscape uncovers reprogrammed pro-tumorigenic neutrophils in the bone marrow.

Prerna Magod1, Ignacio Mastandrea1, Liat Rousso-Noori1, Lilach Agemy2, Guy Shapira3, Noam Shomron3, Dinorah Friedmann-Morvinski4.   

Abstract

Recent multi-omics studies show different immune tumor microenvironment (TME) compositions in glioblastoma (GBM). However, temporal comprehensive knowledge of the TME from initiation of the disease remains sparse. We use Cre recombinase (Cre)-inducible lentiviral murine GBM models to compare the cellular evolution of the immune TME in tumors initiated from different oncogenic drivers. We show that neutrophils infiltrate early during tumor progression primarily in the mesenchymal GBM model. Depleting neutrophils in vivo at the onset of disease accelerates tumor growth and reduces the median overall survival time of mice. We show that, as a tumor progresses, bone marrow-derived neutrophils are skewed toward a phenotype associated with pro-tumorigenic processes. Our findings suggest that GBM can remotely regulate systemic myeloid differentiation in the bone marrow to generate neutrophils pre-committed to a tumor-supportive phenotype. This work reveals plasticity in the systemic immune host microenvironment, suggesting an additional point of intervention in GBM treatment.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cancer stem cells; glioblastoma; mouse models of cancer; neutrophils; plasticity; systemic reprogramming; tumor microenvironment

Mesh:

Substances:

Year:  2021        PMID: 34348160     DOI: 10.1016/j.celrep.2021.109480

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  8 in total

1.  ICAM-1 on Breast Cancer Cells Suppresses Lung Metastasis but Is Dispensable for Tumor Growth and Killing by Cytotoxic T Cells.

Authors:  Ofer Regev; Marina Kizner; Francesco Roncato; Maya Dadiani; Massimo Saini; Francesc Castro-Giner; Olga Yajuk; Stav Kozlovski; Nehora Levi; Yoseph Addadi; Ofra Golani; Shifra Ben-Dor; Zvi Granot; Nicola Aceto; Ronen Alon
Journal:  Front Immunol       Date:  2022-07-11       Impact factor: 8.786

2.  Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity.

Authors:  Agnieszka Chryplewicz; Julie Scotton; Mélanie Tichet; Anoek Zomer; Ksenya Shchors; Johanna A Joyce; Krisztian Homicsko; Douglas Hanahan
Journal:  Cancer Cell       Date:  2022-09-15       Impact factor: 38.585

Review 3.  Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.

Authors:  Lizhi Pang; Fatima Khan; Amy B Heimberger; Peiwen Chen
Journal:  Trends Cancer       Date:  2022-05-24

4.  Multimodal imaging of the dynamic brain tumor microenvironment during glioblastoma progression and in response to treatment.

Authors:  Anoek Zomer; Davide Croci; Joanna Kowal; Leon van Gurp; Johanna A Joyce
Journal:  iScience       Date:  2022-06-09

Review 5.  Glioblastoma Microenvironment and Cellular Interactions.

Authors:  Carmen-Bianca Crivii; Adina Bianca Boșca; Carmen Stanca Melincovici; Anne-Marie Constantin; Mariana Mărginean; Eleonora Dronca; Rada Suflețel; Diana Gonciar; Maria Bungărdean; Alina Șovrea
Journal:  Cancers (Basel)       Date:  2022-02-21       Impact factor: 6.639

6.  Isolation and characterization of the immune cell fraction from murine brain tumor microenvironment.

Authors:  Ignacio Mastandrea; Divsha Sher; Prerna Magod; Dinorah Friedmann-Morvinski
Journal:  STAR Protoc       Date:  2022-01-20

7.  Myeloperoxidase exerts anti-tumor activity in glioma after radiotherapy.

Authors:  Muhammad Ali; Giulia Fulci; Mantas Grigalavicius; Benjamin Pulli; Anning Li; Gregory R Wojtkiewicz; Cuihua Wang; Kevin Li-Chun Hsieh; Jenny J Linnoila; Theodossis A Theodossiou; John W Chen
Journal:  Neoplasia       Date:  2022-03-02       Impact factor: 5.715

Review 8.  Neutrophils: New Critical Regulators of Glioma.

Authors:  Guanyu Wang; Jinpeng Wang; Chaoshi Niu; Yan Zhao; Pengfei Wu
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.